Advanced NSCLC: Pembrolizumab-treated never-smokers have a shorter survival than ever-smokersJune 22, 2022Lung Cancer
ALK+ advanced NSCLC with brain mets: Lorlatinib boosts PFS, reduces CNS progressionJune 22, 2022Lung Cancer
Recurrent or metastatic NSCLC: Tiragolumab plus atezolizumab combo shows promiseJune 22, 2022Lung Cancer
Oncology PracticePromising treatment option for incurable lung cancer described as ‘significant’June 13, 2022Lung CancerASCO Lung Cancer
Oncology PracticeImmunotherapy treatment combo charts new course for resectable NSCLC treatmentJune 3, 2022Lung Cancer
Oncology PracticeClimate change and air pollution seen through the cancer lensMay 26, 2022Lung CancerMixed Topics
Advanced squamous NSCLC: NFE2L2 and KEAP1 mutations tied to worse real-world PFSMay 24, 2022Lung Cancer
